GlassScriptPhysician profile
Ravneet Riar
NPI 1417184078
$5,233.82
in general payments reported to CMS, 2019-2025
34 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $81.03 · 2021: $676 · 2022: $1,128 · 2023: $1,069 · 2024: $726 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.12 |
| Education | $278.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $813.30 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $709.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.17 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Inspire Medical Systems, INC. | $417.85 | 2023-2025 | Inspire |
| Astellas Pharma US INC | $325.04 | 2024-2025 | Ambisome, Cresemba |
| Jazz Pharmaceuticals INC. | $270.36 | 2025 | |
| United Therapeutics Corporation | $214.77 | 2021-2025 | Tyvaso, Orenitram |
| Insmed, INC. | $192.14 | 2021-2024 | Arikayce |
| Mylan Specialty L.P. | $145.37 | 2021-2023 | Yupelri |
| Genzyme Corporation | $134.01 | 2025 | |
| Intuitive Surgical, INC. | $129.87 | 2022 | |
| Harmony Biosciences LLC | $125.73 | 2022-2024 | |
| Abbvie INC. | $123.72 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $97.47 | 2022-2025 | Pifeltro |
| Grifols USA, LLC | $89.25 | 2021-2024 | Prolastin-C Liquid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $86.63 | 2023-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $83.21 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $78.21 | 2021-2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $76.16 | 2019 | |
| Electromed, INC. | $65.96 | 2023-2025 | Smartvest |
| Amgen INC. | $64.74 | 2022-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $45.50 | 2022 | |
| Pulmonx Corporation | $42.41 | 2023-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Janssen Pharmaceuticals, INC | $42.06 | 2021 | |
| La Jolla Pharmaceutical Company | $37.40 | 2021-2024 | Giapreza |
| Takeda Pharmaceuticals U.S.A., INC. | $26.76 | 2021 | |
| Aimmune Therapeutics, INC. | $24.83 | 2025 | Vowst |
| Mayne Pharma Commercial LLC | $23.50 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.23 | 2022 | |
| Philips North America LLC | $20.62 | 2022 | |
| Shionogi INC | $16.58 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $14.20 | 2024 | Lumryz |
| Emd Serono, INC. | $13.91 | 2025 | |
| Baxter Healthcare | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravneet Riar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.